Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Freeman Spogli investment in EverVet
We advised Tailwind Capital and EverVet on the transaction
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff
Oak Street Health $180.3 million secondary offering
We advised the joint book-running managers on the equity offering
Tenaya Therapeutics $75 million at-the-market offering
The common stock is listed on the Nasdaq Global Select Market
ADC Therapeutics $175 million term loan facility and other financings
We advised the company on the new facility, a $115 million exchange and a $6.25 million share sale
Terns Pharmaceuticals $65 million common stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InSilico Medicine $35 million Series D2 financing
We are advising InSilico Medicine on the financing
Vaccitech $75 million at-the-market offering
The ADSs are listed on the Nasdaq Global Market
RxSight $50 million at-the-market offering
The stock is listed on the Nasdaq Global Market
TransMedics Group $150 million follow-on offering
The shares are listed on the Nasdaq Global Select Market